Akari therapeutics, plcAKTX.US Overview

US StockHealthcare

(No presentation for AKTX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

AKTX Overall Performance

AKTX AI Analysis & Strategy

AKTX Recent Performance

4.45%

Akari therapeutics, plc

0.81%

Avg of Sector

-1.14%

S&P500

AKTX PowerScanner

AKTX Key Information

AKTX Valuation Metrics

AKTX Earnings Table

AKTX Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.